B rain metastasis (BM) occurs in 20%-50% of cancer patients during the course of their disease. 15, 26 For these patients, it is well established that whole brain radiation therapy (WBRT) prolongs survival compared with observation or steroid treatment. 3, 8, 8 However, adding WBRT to stereotactic radiosurgery (SRS) 2, 7, 17 or surgery 17, 23, 27 does not alter the survival rate for patients with up to 4 BMs. 20, 22, 24, 29, 34 Moreover, randomized studies suggest that WBRT increases cognitive impairment, either when administered as an addition to SRS 6 or as prophylactic irradiation.
mary aim is palliation through local disease control while minimizing treatment-related complications. Therefore, further evaluation is needed for treatment regimens that minimize neurological toxicity.
Currently, Gamma Knife radiosurgery (GKRS) is increasingly used as the sole treatment for BM, 19 because studies suggest that the effect on survival of GKRS alone is similar to that of GKRS combined with WBRT. 2, 7, 17, 27 Because GKRS is based on converging beams, which sharply decrease the radiation dose, it may be associated with a more favorable toxicity profile. However, few data are available regarding QOL after exclusive use of GKRS. 11 We therefore conducted a prospective study in a cohort of patients with BM to measure QOL as the primary end point before and repeatedly for 12 months after GKRS. We aimed to analyze QOL after GKRS according to the disease course and identify potential baseline predictors for QOL.
Methods

Study Design
QOL was measured using the Functional Assessment of Cancer Therapy-Brain (FACT-BR) questionnaire before treatment and at 1, 3, 6, 9, and 12 months after GKRS. The FACT-BR is validated for primary brain tumors and BM. 35 Secondary end points were clinical outcome, toxicity defined by the common toxicity criteria 33 and the European Organisation for Research and Treatment/Radiation Therapy Oncology Group (EORTC/RTOG) criteria of late effects, 10 overall survival, and freedom from brain progression/duration of local control after GKRS. Ethics approval was obtained from the regional ethics committee.
All patients with BM referred for GKRS from May 2010 until September 2011 were evaluated for the study. Inclusion criteria were 1) age > 18 years; 2) Karnofsky Performance Scale (KPS) score ≥ 70 and recursive partitioning analysis (RPA) 14 Class ≤ 2 at the time of referral; 3) total tumor volume ≤ 25 cm 3 ; 4) ≤ 6 BMs; and 5) written consent. Exclusion criteria were 1) GKRS not feasible or surgery indicated because of high intracerebral pressure (ICP); 2) prior diagnosis of primary brain tumor; and 3) prior GKRS.
Our aim was to obtain a study cohort representative of daily clinical practice; thus, prior surgery or WBRT, or both, were not regarded as exclusionary criteria, despite possible neurocognitive implications. The decision regarding enrollment was made at the time of referral. The condition of 12 patients deteriorated from the time of referral to admission (RPA Class 3/KPS score 60).
In 115 consecutive patients, 15 were not included due to the following reasons: refusal (4 patients), KPS score < 70 (5 patients), too many lesions (5 patients), or previous brain tumor (1 patient). Among 100 included patients, 1 was excluded because of tumor growth through the foramen magnum and 2 because a primary brain tumor was suspected on the basis of treatment MRI findings, leaving 97 patients in the study. The study was closed when the last enrolled patient had been followed for 12 months.
Statistical Analysis
A mixed linear model was used for statistical analysis. The mixed linear model was chosen due to the heterogeneity in the cancer population as it allows for individual starting points of the regression lines (intercepts) and accounts for correlation between measurements at different time points within each individual.
For each QOL scale, a set of mixed linear regression analyses 4 was performed using the 6 study time points as within-patient factors, assuming an autoregressive correlation structure of the first order. In all models, the months since GKRS, age, and sex were included as covariates (Model 1). The mixed linear model ensures that repeated measures in the same patient are not evaluated as independent observations, and the development over time is estimated individually for each patient before a general trend is estimated. It also ensures that patients with some missing values are not excluded totally from the analysis, but contribute to the results at the time points where there are values, e.g., patients who died before the end of follow-up were included until death.
Part 1
First, variables recorded during follow-up regarding clinical and radiological status were analyzed one at a time with adjustment only for time point, age, and sex. Variables recorded during follow-up were as follows: 1) change in cerebral symptoms (0 = improved, 1 = unchanged, 2 = worse); 2) development of new extracerebral symptoms (0 = yes, 1 = no); 3) change in steroid treatment (0 = never used, 1 = discontinued/reduced, 2 = unchanged/ increased); 4) local failure of 1 or more BM (0 = yes, 1 = no); 5) RTOG complications (0 = RTOG, 1 = RTOG 1, 2 = RTOG 3); 6) distant failure (0 = yes, 1 = no); and 7) extracerebral disease progression (0 = yes, 1 = no). Second, all variables were included in a starting model before exclusion of the least significant variable in a backward stepwise manner that was performed until only time, age, sex (forced into the models), and covariates with p ≤ 0.05 for removal remained. Results are given for each explanatory variable as the estimated regression coefficient (b) with 95% CIs.
Part 2
Potential baseline predictors for QOL were analyzed first, with the addition of one of the other baseline covariates at a time (Model 2a, b…j) and testing of any interactions between each of these and time since GKRS. Thereafter, all variables were included in a starting model before exclusion of the least significant variable in a backward stepwise manner that was performed until only time, age, sex (forced into the models), and covariates with p ≤ 0.05 for removal remained. To this model, we added the most significant interactions with p ≤ 0.05 between time and the other variables in a forward stepwise manner.
In Part 2 models, a change of QOL over time was modeled using a specific time variable. All tests for parameters including this time variable are about changes in QOL over time, and tests for parameters not involving the time variable apply to QOL itself. Kaplan-Meier survival analysis was performed. Statistical significance was set at p ≤ 0.05. All analyses were performed using SPSS (version 20, IBM).
Results
Overall Survival and Local Tumor Control
At the end of the study, 23 (24%) of 97 patients were alive and censored. Median survival was 7.5 months (95% CI 5.0-10.0 months). During the 12-month follow-up, 74 patients died, 58 (78%) due to extracerebral causes and 16 (22%) due to intracerebral causes. The intracerebral causes of death were intratumoral bleeding (6 patients), local failure (1 patient), multiple new lesions left untreated (1 patient), and a combination of extracerebral disease progression and local failure (4 patients)/distant failure (4 patients) in which salvage treatment for intracerebral failure was initiated shortly before death.
Follow-up MR images were available for 87 patients (200 of 225 tumors). Local control was achieved for 174 (87%) of the BMs in 67 (77%) of these patients. Freedom from progression of all treated BMs was 93% at 6 months and 75% at 1 year.
Clinical Outcome
The numbers of patients available/alive for clinical follow-up at 1, 3, 6, 9, and 12 months were 91/91 (100%), 80/81 (99%), 53/53 (100%), 40/43 (93%), and 33/34 (97%), respectively. At the 1-month interview, 78 (86%) of 91 patients reported improved/unchanged cerebral symptoms. These percentages remained stable at 3 (86%), 6 (89%), 9 (83%), and 12 (91%) months (Fig. 1A) . Median time to improvement was 1.0 months (range 1-12 months). At 1 month after GKRS, 61 patients (68%) exhibited stable or improved KPS scores. Twenty-nine patients (32%) reported a reduced KPS score at 1 month that was due to infection, possibly related to chemotherapy and/or dexamethasone (8 patients), pain (5 patients), tiredness (5 patients), deep vein thrombosis (1 patient), and cerebral symptoms (10 patients).
Overall QOL
The numbers of patients completing the FACT-BR at baseline and at 1, 3, 6, 9, and 12 months were 94/97 (97%), 78/88 (89%), 64/76 (84%), 41/50 (82%), 33/42 (79%), and 25/32 (78%), respectively. Seventy-one (73%) of the 97 patients completed all QOL questionnaires from baseline until death. The reasons why 26 patients (27%) did not complete all QOL questionnaires were as follows: 12 patients (12.4%) did not deliver the last questionnaire because of reduced general condition due to cancer or its treatment; 9 (9.3%) either refused, forgot, or incompletely The average for all 5 subscores and 2 of 3 summed scores (total and TOI) remained unchanged up to 12 months after GKRS (Table 3 , Fig. 1B-D) . Mean values for surviving patients increased for the FACT-G, although it dropped for each individual by 0.517 points per month of follow-up (p = 0.025).
According to MIDs, the BRCS was improved or unchanged compared with baseline for 64%, 60%, 66%, 72%, and 60% of the patients at 1, 3, 6, 9, and 12 months, respectively ( Fig. 1E and F).
Part 1: Disease Course and QOL After GKRS
We recorded local control, symptomatic relief, reduced need for steroids, and occurrence of complications or disease progression at 1, 3, 6, 9, and 12 months of follow-up.
Local Recurrence and Distant Failure
Local recurrence occurred in 26 (12%) of the treated tumors in 20 patients. Fourteen of these patients were treated using GKRS as a salvage treatment, 3 had their tumor recurrence resected, 1 had a tumor irradiated with fractionated radiation (FR), and 2 were not retreated. Distant failure was observed in 49 (51%) of 97 patients during follow-up. New lesions were treated with 1 or more subsequent GKRS sessions in 32 patients (33%) and FR in 13 patients (13%). Of these, 4 patients underwent retreatment with both GKRS and FR. Because of reduced general condition or multiple new lesions after prior FR, no treatment was initiated in 8 patients (8%) with distant failure. The median time to distant failure was 3.0 months (range 1-18 months). Leptomeningeal spread was noted in 7 (7%) of the patients; however, the QOL within the first 12 months after GKRS was recorded in only 5 (5%) of these patients.
QOL was not affected by local or distant progression, including leptomeningeal spread, except for PWB, which was negatively correlated with local progression in the multivariate analysis below.
Symptomatic Efficacy of GKRS
Patients with improved cerebral symptoms after GKRS reported a 4.6-point higher BRCS score than patients who experienced clinical deterioration. Similarly, patients with unchanged symptoms, including asymptomatic patients at baseline who remained asymptomatic at follow-up, reported a 5.2-point higher BRCS score than those who deteriorated (p = 0.007, Fig. 2A ). The median duration to deterioration was 3.0 months (range 1-12 months).
For the 73 patients (73%) treated with dexamethasone before GKRS, steroid treatment was discontinued after GKRS in 28 (30%), reduced in 20 (22%), kept unchanged in 9 (10%), and increased in 11 patients (12%) during follow-up. Twenty-four patients (26%) did not use steroids either before or after GKRS. QOL was higher for patients who never used steroids (BRCS 7.3 points, total 12.3 points) or those in whom the dose was reduced (BRCS 2.5 points), compared with patients whose dose had to be increased after GKRS (BRCS, p = 0.006; total, p = 0.031).
Complications
Two patients (2.3%) experienced transient focal hair loss. Late adverse effects, RTOG Grade 1 or 2, were noted in 9 (10.5%) and 5 patients (5.8%), respectively. There were no Grade 3 or 4 complications. RTOG complications occurred at a median of 6.0 months (range 1-27 months) after GKRS but were not associated with a low QOL (Table 5).
Extracerebral Disease Progression
Extracerebral disease progressed in 66 patients (72.5%) and in 59 (89.4%) of these within the 12 months that QOL was recorded. At the time of progression, patients reported 4.8 BRCS points (p < 0.001, Fig. 2B ) and 5.1 total points (p = 0.041), indicating lower QOL than patients without progression (Table 5) . Of these 59 patients, 37 (62.7%) had symptomatic progression. Patients who were symptomatic due to extracerebral progression reported a 3.4-point lower BRCS score (p = 0.026) and a 7.2-point lower total score than patients who were asymptomatic (p = 0.019, Table 5 ). Targeted therapy, administered to 19 (19.6%) of the included patients, did not significantly impact QOL.
Multivariate Analyses of QOL Related to Clinical and Radiological Variables After GKRS
After multivariate analysis, improved or unchanged cerebral symptoms (BRCS, p = 0.005; Total, p = 0.014) and lack of steroid treatment (PWB, p = 0.003) remained associated with high QOL at 1, 3, 6, 9, and 12 months of follow-up.
Extracerebral disease progression (BRCS, p = 0.001; total, p = 0.025), especially if symptomatic (BRCS, p = 0.037), and local failure (PWB, p = 0.018) were correlated with low QOL (Table 6 ).
Part 2: Potential Baseline Predictors for QOL After GKRS
Baseline Factors Predicting High and Retained QOL During Follow-Up
Patients with asymptomatic BMs reported a 13.0-point higher BRCS score and a 29.3-point higher total score at any time point than symptomatic patients (Fig. 2C , Table  7 ). Even patients whose symptoms disappeared with steroid use prior to GKRS scored 7.0 and 13.2 points higher than symptomatic patients on the BRCS and total scores, respectively (BRCS, p < 0.001; total, p < 0.001). Patients presenting without seizures scored 4.8 and 11.4 points higher than patients with seizures on the BRCS (p = 0.043) and total score (p = 0.024), respectively. Patients without cognitive impairment reported a 6.8-point higher BRCS score (p = 0.006) and an 11.7-point higher total score (p = 0.031) than patients with cognitive deficits. A high baseline KPS score was associated with high QOL; the BRCS score was 3.3 points (p < 0.001) and the total score 6.4 points (p < 0.001) higher for every 10 points of KPS scored (Fig.  2D , Table 7 ). Patients with peritumoral edema < 20 ml at GKRS reported a 4.4-point higher BRCS score (p = 0.042) than those with extensive edema, and patients treated with optimal margin doses had higher QOL than patients treated with suboptimal prescription doses, independent of the time since GKRS. The BRCS score was 8.7 and 2.6 points higher (p = 0.005) and the total score was 13.8 and 1.7 points higher (p = 0.025) if patients were treated with margin doses of 23-25 Gy or 20-22 Gy, respectively, compared with < 20 Gy. Patients who had previously undergone resection for BM scored higher for SWB (p = 0.008) and FACT-G (p = 0.035).
The number of BMs (1-6), total BM volume, tumor location or primary histopathology, or cancer subtypes, including mutation status for melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and breast cancer, had no impact on QOL. Prior WBRT did not affect QOL (Table 7). Baseline Predictors for Improved/Reduced QOL During Follow-Up
Patients with RPA Class 3 had low baseline PWB QOL that improved by 0.44 points during each month of follow-up, whereas it dropped 0.44 points for RPA Class 1 with high baseline values and remained unchanged for patients with RPA Class 2 (PWB, p = 0.031; Fig. 2E ). In patients with adrenal metastases at baseline the PWB QOL dropped 4.0 points in total score per month, whereas in patients without adrenal metastases the PWB QOL dropped only 0.5 points a month (p = 0.022; Fig. 2F ). Notably, extracerebral disease to lung, liver, bone, or lymph nodes did not affect QOL.
Multivariate Analyses of Baseline Predictors for QOL
Asymptomatic BM (BRCS, p = 0.001; total, p < 0.001), high KPS score (BRCS, p = 0.017; total, p = 0.002), low RPA class (BRCS, p = 0.049), lack of seizures (BRCS, p = 0.040), and absence of cognitive impairment (BRCS, p = 0.033) remained positive predictive factors for QOL BRCS score. Patients treated with optimal margin doses had higher TOI scores (p = 0.038) after multivariate analysis (Table 8) .
Discussion
Potential Benefit of GKRS
As survival for patients with cancer has generally improved in recent years, it is of utmost importance to evaluate QOL in long-term survivors. The proportion of surviving patients in a BM patient cohort always declines over time, but our results still reflect QOL reported by 78%-89% of the patients alive at 1, 3, 6, 9, and 12 months of follow-up. A major challenge to QOL studies is the number of patients lost to follow-up. 18, 30 In our referral area, both the low geographical mobility and the presence of centralized registries allow for standardized follow-up. Thus, we obtained data from 97% of the patients at baseline, and the compliance rate remained high during follow-up. This was a single-center study, and demographic characteristics may have different impacts at other institutions.
In the present study, the 1-year survival rate was 24% (23 patients). Notably, QOL remained stable for these longterm survivors, unaffected by the fact that median survival was only 7.5 months, and the percentage of symptom-free patients also remained stable for as long as 12 months of follow-up. It is likely that asymptomatic patients with local tumor control and no treatment-related complications also report high QOL. This was also the case in our present study, in which high QOL was associated with local tumor control at follow-up, relief of cerebral symptoms, and reduced need for steroids.
Patients with extensive peritumoral edema at the time of GKRS who often required steroids, with their inherent risk of complications, reported lower QOL during follow-
FIG. 2. A:
Mean QOL BRCS scores in patients reporting improved, unchanged, or worse cerebral symptoms at each follow-up evaluation 1-12 months after GKRS for BM. B: Mean QOL BRCS scores in patients with extracerebral disease progression compared with patients with stable peripheral disease during follow-up. C: Mean QOL BRCS scores during follow-up after GKRS according to symptomatic versus asymptomatic BM at baseline. D: Mean QOL BRCS scores during follow-up after GKRS according to KPS score at baseline. E: Mean QOL PWB scores during follow-up after GKRS for BM according to RPA class at baseline. F: Mean QOL total scores during follow-up after GKRS for BMs according to presence versus absence of adrenal metastases at baseline. SE = standard error. up than those without pretreatment edema. This negative effect on QOL emphasizes the importance of reducing steroids to the lowest necessary dose and weaning off of steroids completely as soon as possible after GKRS. Interestingly, patients did not report impaired QOL if adverse radiation effects occurred. The reason may be that adverse radiation events are often a transient radiological finding with few or no symptoms, and only a third of the patients with adverse radiation events in this study needed symptomatic steroidal treatment. Notably, new BM and leptomeningeal spread were not associated with lower QOL at follow-up. This may seem counterintuitive and a phenomenon of patients lost to follow-up, as only 64 of the original 97 patients were available for QOL testing at 6 months and 25 of 97 were available at 12 months after initial SRS. The mixed linear model analysis assumes data are missing at random or missing completely at random, but a selection bias may be present, if missing data are dependent on QOL (missing not at random). 28 However, distant failures are often asymptomatic but are detected early due to routine imaging every 3 months after GKRS, and thus are treated before symptoms develop. Leptomeningeal spread was diagnosed only in 5 patients within the time frame that QOL was reported, and in 4 of these, leptomeningeal spread was detected at the last follow-up evaluation before death. This may explain why the FACT-BR was not sufficiently sensitive to detect QOL impairment in these few patients.
Extracerebral Disease Progression
Most patients died due to extracerebral disease progression. In the present study extracerebral disease progression was associated with low QOL, probably due to a combination of symptoms, treatment-related complications, and the psychological effects related to cancer progression. Although QOL is reduced at the time of progression, it may improve for each individual patient at the next follow-up, depending on whether the disease has been stabilized on local treatment or progressed further. One therefore has to be cautious when interpreting QOL in patients with cancer. QOL is not only a result of the initial GKRS but also reflects the effects and side effects of subsequent treatments during the disease course. This may explain why individual QOL curves vary over time and why QOL mean values remain stable despite progression in peripheral disease in the majority of patients. Thus, QOL appears to remain stable until death related to the cancer disease itself, with the use of GKRS for BM.
Maintained QOL or a "Survival of the Fittest" Effect
Dying patients are likely to be noncompliant with reduced QOL, and a "survival of the fittest" effect may also explain why mean QOL is stable over 12 months. This theory is supported by the fact that although mean QOL values remain stable or even appear to improve during follow-up, individual time trends are negative. A significant negative time trend was, however, found only for the FACT-G score, whereas the other scores exhibited stable individual time trends. Moreover, it should be emphasized that the clinical outcome data in this study included 93%-100%, and data were thus available for many of the patients missing from the QOL evaluation, because it was assessed during a telephone interview before the questionnaires were sent by mail. Notably, the fraction with stable/ improved KPS scores at the 1-month follow-up, and the fraction reporting stable or improved cerebral symptoms (clinical outcome), were similar to the fraction reporting stable/improved QOL. This finding does not support the noncompliance theory. Some dying patients may not necessarily report reduced QOL if they have come to terms with the inevitable outcome of their disease, and symptoms are alleviated by medications. Although QOL mean values remained stable, according to MIDs, the QOL BRCS score improved in nearly two-thirds of the patients at 9 months after GKRS. We were not able to identify a common baseline predictor for improved brain subscore in these patients. Adrenal metastasis at baseline, a sign of extensive disseminated disease, did, however, predict a reduction in QOL BRCS score after GKRS. Accordingly, patients with high KPS scores at baseline, indicating a more controlled systemic disease, reported higher QOL BRCS scores than patients with lower KPS scores at all evaluation time points.
The only baseline factor predicting a significant positive change in QOL was high baseline RPA class. These patients declined in KPS score shortly after referral, most probably due to the cerebral lesions. A significantly lower QOL score at baseline compared with RPA Class 1 and 2 patients allowed for improvement in QOL during followup. Interestingly, RPA Class 3 patients thus benefited most from treatment, although they were considered to be the least well suited for treatment and thus were excluded from the study if known at referral. A stable QOL reflecting high local control rates and low complication rates may be a good outcome, considering the lethal nature of this disease. Because baseline scores in the present study were close to those for the healthy population, improved QOL may not be expected.
Addeo et al. registered a significantly improved FACT-G score when temozolomide was administered concomitantly with WBRT for BMs, compared with WBRT alone. 1 They registered FACT-G scores of 40-50 at baseline, and 60-70 at 6 months. Thus, their QOL scores were lower at baseline, allowing improvement to occur. DiBiase et al. reported stable or improved QOL after GKRS in 8 of 10 patients with stable intracerebral and extracerebral disease. However, QOL decreased in 3 patients with intracerebral and in 7 of 8 patients with extracerebral disease progression. 11 
Treatment Options for Patients With Brain Metastases
Currently SRS, surgery, and WBRT, either alone or in combination, are treatment options for patients with BM. QOL is essential when deciding on the treatment modality for BM, but limited data are available regarding the effect of GKRS on QOL. In light of previous studies showing that the addition of WBRT to SRS increases local and distant control rates, it is noteworthy that local progression was not negatively associated with QOL in our study for any of the summed scores and only 1 of the subscores (PWB). Moreover, distant failure did not negatively impact QOL in our study. WBRT may impair cognitive function, and several studies suggest that it negatively influences QOL. The randomized study by Sofietti et al. comparing treatment with surgery, GKRS, or a linear accelerator (LINAC) with or without WBRT showed higher QOL if adjuvant WBRT was not given. 30 In a prospective followup of 60 patients with BMs, Doyle et al. reported that QOL (using the FACT-BR) worsened 2 months after WBRT. 12, 36 In our present study, overall QOL remained stable during the 12-month follow-up for 7 of 8 QOL dimensions examined. This is consistent with the study by Soffietti et al. comparing surgery, GKRS, or LINAC with or without WBRT, which also showed stable QOL following SRS. 30 However, of the 185 patients treated with SRS with or without WBRT, only 53 received GKRS versus 132 patients treated with LINAC, and the compliance rate was limited (45% at 1-year follow-up).
Because we investigated patients treated exclusively with GKRS using a brain cancer-dedicated questionnaire, we believe this strengthens the relevance of our findings to the setting of GKRS treatment for BM. Because GKRS is appropriate on demand if new BMs occur during followup and as salvage treatment for small BMs, we believe our results support reservation of WBRT for patients not suitable for SRS. In summary, QOL can be viewed as a balance between minimizing treatment complications and maximizing benefits. 35 GKRS may reduce problems relating to both radioresistance and neurotoxicity. Thus, a favorable complication profile may be the strongest justification for choosing GKRS as primary treatment.
Conclusions
QOL is maintained until death related to the cancer disease itself when GKRS is used for BM. The highest QOL is noted for patients with local control, improved symptoms, or reduced need for steroids and reflects successful GKRS, whereas low QOL is noted with local failure, increased need for steroids, or progression of the peripheral disease. Survival is an important end point, but so is QOL. Considering a high local control rate, low complication rate, and a survival rate comparable to that of other treatment alternatives, these data support the use of GKRS for patients with BM.
